Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

Cellectar Biosciences Inc

Healthcare US CLRB

2.5USD
-0.07(2.72%)

Last update at 2026-06-23T20:00:00Z

Day Range

2.502.66
LowHigh

52 Week Range

2.4320.59
LowHigh

Fundamentals

  • Previous Close 2.57
  • Market Cap12.04M
  • Volume59268
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-22.76625M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-8.35

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -21.79104M -44.51545M -42.83061M -28.66125M -24.12236M
Minority interest - - - - -
Net income -21.79104M -44.58145M -42.77061M -28.60125M -23.97016M
Selling general administrative 11.48M 25.64M 11.69M 9.59M 6.54M
Selling and marketing expenses - 0.95M 0.95M - -
Gross profit -0.21360M -0.29165M -0.19237M - -
Reconciled depreciation 0.21M 0.29M 0.16M 0.15M 0.15M
Ebit -22.97984M -51.77770M -38.96064M -28.96221M -24.28120M
Ebitda -22.76625M -51.48604M -38.76827M -28.81377M -24.13128M
Depreciation and amortization 0.21M 0.29M 0.19M 0.15M 0.15M
Non operating income net other - - - - -
Operating income -22.97984M -51.77770M -38.96064M -28.81377M -24.13128M
Other operating expenses 22.98M 51.78M 38.96M 28.81M 24.13M
Interest expense - - - -0.30095M 0.00228M
Tax provision 0.00000M 0.07M -0.06000M -0.06000M -
Interest income 0.44M 1.21M 0.40M 0.15M 0.00228M
Net interest income 0.44M 1.21M 0.40M 0.15M 0.00228M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - 0.07M -0.06000M -0.06000M -0.15220M
Total revenue 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Total operating expenses 22.77M 51.78M 38.96M 28.81M 24.13M
Cost of revenue 0.21M 0.29M 0.19M - -
Total other income expense net 1.19M 7.26M -3.86997M 0.15M 0.00892M
Discontinued operations - - - - -
Net income from continuing ops -21.79104M -44.58145M -37.74993M -28.60125M -24.12236M
Net income applicable to common shares - - - -28.60125M -24.12236M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 14.98M 25.47M 12.08M 21.59M 37.20M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 0.84M 0.96M 0.89M 0.66M 0.87M
Total liab 5.06M 11.18M 13.43M 6.08M 4.16M
Total stockholder equity 9.92M 14.29M -1.35605M 15.51M 33.05M
Deferred long term liab - - - - -
Other current liab 3.21M 5.20M 7.26M 2.92M -0.00009M
Common stock 0.00004M 0.00046M 0.00021M 0.00009M 0.00061M
Capital stock 0.52M 0.52M 6.06M 1.38M 1.38M
Retained earnings -269.13350M -247.34246M -217.48254M -179.49904M -150.89779M
Other liab - - - - -
Good will - - - - -
Other assets - - - 0.08M 0.08M
Cash 13.20M 23.29M 9.56M 19.87M 35.70M
Cash and equivalents - - - - -
Total current liabilities 4.75M 9.39M 12.94M 5.53M 3.99M
Current deferred revenue - - - - 2.44M
Net debt -12.78645M -22.79460M -9.01201M -19.26253M -35.40223M
Short term debt 0.10M 0.08M 0.06M 0.05M 0.14M
Short long term debt - - - - -
Short long term debt total 0.41M 0.49M 0.55M 0.60M 0.30M
Other stockholder equity 277.15M 261.12M 211.45M 193.62M 182.56M
Property plant equipment - - - 0.98M 0.55M
Total current assets 14.04M 24.25M 10.45M 20.53M 36.57M
Long term investments - - - - -
Net tangible assets - - - 14.13M 31.66M
Short term investments - - - - -
Net receivables - - - - -
Long term debt - - - - -
Inventory - - - - -
Accounts payable 1.44M 4.11M 5.62M 2.56M 1.42M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - -1.38202M - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.03M 0.03M 0.03M 0.08M 0.08M
Deferred long term asset charges - - - - -
Non current assets total 0.94M 1.22M 1.62M 1.06M 0.63M
Capital lease obligations 0.41M 0.49M 0.55M 0.60M 0.30M
Long term debt total - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - -0.10419M -0.71514M -0.22597M -0.14136M
Change to liabilities - - - 1.62M 0.41M
Total cashflows from investing activities -0.00588M -0.10419M -0.86404M -0.22597M -0.14136M
Net borrowings - - - - -
Total cash from financing activities 13.03M 61.41M 22.94M 9.61M 1.25M
Change to operating activities - - - 0.06M -0.21296M
Net income -21.79104M -44.58145M -42.77061M -28.60125M -24.12236M
Change in cash -10.09257M 13.72M -10.30137M -15.83762M -21.46140M
Begin period cash flow 23.29M 9.56M 19.87M 35.70M 57.17M
End period cash flow 13.20M 23.29M 9.56M 19.87M 35.70M
Total cash from operating activities -23.11822M -47.58300M -32.37697M -25.22230M -22.56884M
Issuance of capital stock 5.79M 0.00000M 31.76M 9.61M 0.03M
Depreciation 0.21M 0.29M 0.19M 0.15M 0.15M
Other cashflows from investing activities - - - - -
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables - - - - -
Sale purchase of stock - - - - -
Other cashflows from financing activities 13.03M 61.41M 22.94M -0.22597M 1.21M
Change to netincome - - - 1.55M 1.20M
Capital expenditures 0.00588M 0.10M 0.86M 0.23M 0.14M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -3.12698M -1.72572M 3.48M 1.68M 0.20M
Stock based compensation 2.26M 4.27M 2.41M 1.45M 1.12M
Other non cash items -0.67751M -5.84026M 4.32M 0.09M 0.08M
Free cash flow -23.12410M -47.68720M -33.24101M -25.44827M -22.71020M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
CLRB
Cellectar Biosciences Inc		 -0.07 2.72% 2.50 - - 348.47 1.56 314.45 -3.2524
NVO
Novo Nordisk A/S		 1.54 3.36% 47.42 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 - -% 45.00 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 1.63 0.35% 468.42 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 5.53 0.90% 618.03 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer in the United States. The company's lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer. It also develops CLR125, an iodine-125 Auger-emitting radioconjugate program; and CLR 225, an actinium-225 based program. The company has collaborative with Orano Med to develop alpha emitter lead-212 conjugated to phospholipid ether series; and LegoChem Bio. Cellectar Biosciences, Inc. was founded in 2002 and is headquartered in Florham Park, New Jersey.

Cellectar Biosciences Inc

100 Campus Drive, Florham Park, NJ, United States, 07932

Key Executives

Name Title Year Born
Mr. James V. Caruso Pres, CEO & Director 1959
Mr. Jarrod Longcor Chief Operating Officer 1973
Mr. Chad J. Kolean CPA, CPA CFO & Sec. 1964
Mr. Shane Lea Chief Commercial Officer NA
Mr. James V. Caruso President, CEO & Director 1959
Mr. Chad J. Kolean CPA VP, CFO & Secretary 1964
Mr. Darrell Shane Lea Chief Commercial Officer 1973
Dr. Andrei Shustov M.D. Senior Vice President of Medical 1971
Mr. Darrell Shane Lea Chief Commercial Officer 1974
Dr. Andrei Shustov M.D. Senior Vice President of Medical 1972

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.